About this trial
Degenerative mitral insufficiency secondary to valve prolapse is the most common valve disease in Western countries. In the absence of specific treatment, it spontaneously progresses to heart failure and death when it is severe. Surgical mitral valve repair (or mitral plastic surgery) is the preferred treatment for primary mitral insufficiency by prolapse in case of severe leakage if associated with clinical and/or echocardiographic markers of poor prognosis (i.e., with high risk of morbi-mortality during their follow-up).
It is therefore essential to refine the risk stratification of these patients in order to identify at-risk patients who should potentially benefit earlier from invasive care (cardiac surgery), or conversely, close monitoring.
A number of echocardiographic and MRI parameters may have been associated with a poorer prognosis.
A cohort of patients with primary mitral insufficiency (MI) will be followed to study the relationships of a set of factors to patient prognosis.
Eligibility criteria
Qualifiers
Any patient with primary mitral insufficiency by prolapse (any grade) diagnosed by Trans-Thoracic Echocardiography (TTE)
From November 2010 to April 2019 (retrospective cohort)
From May 2019 to May 2024 (prospective cohort)
No previous surgery of the mitral valve before the first ultrasound
Disqualifiers
Secondary MI
Primary MI without valve prolapse
Active endocarditis
Patient's refusal to participate in the study
Trial design
Treatments tested in this trial
- Echocardiography and MRI
Treatment groups
Sponsors and collaborators
Lille Catholic University
Lead sponsor
University Hospital, Lille
Collaborator